<code id='901FFEA97D'></code><style id='901FFEA97D'></style>

<acronym id='901FFEA97D'></acronym>

<center id='901FFEA97D'><center id='901FFEA97D'><tfoot id='901FFEA97D'></tfoot></center><abbr id='901FFEA97D'><dir id='901FFEA97D'><tfoot id='901FFEA97D'></tfoot><noframes id='901FFEA97D'>

<optgroup id='901FFEA97D'><strike id='901FFEA97D'><sup id='901FFEA97D'></sup></strike><code id='901FFEA97D'></code></optgroup>

<b id='901FFEA97D'><label id='901FFEA97D'><select id='901FFEA97D'><dt id='901FFEA97D'><span id='901FFEA97D'></span></dt></select></label></b><u id='901FFEA97D'></u>

~~<i id='901FFEA97D'><strike id='901FFEA97D'><tt id='901FFEA97D'><pre id='901FFEA97D'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

knowledge

author：Wikipedia 2025-10-02 09:30:10 Page View：5

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

advertisement

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA scientists endorse Pfizer/BioNTech Covid
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

ThisistheinauguraleditionofAdam’sBiotechScorecard,anewsubscriber-onlynewsletter.STAT+subscriberscans

Peter Hotez and the public health issue of online harassment

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Study says nonprofit hospitals fall short in charity care spending

AdobeAnewstudyofhospitals’charitycarespendingsuggestsnonprofithospitalsreallyaren’tthatdifferentfrom

read more